Abstract
One of the main neuropathological lesions observed at brain autopsy of Alzheimers disease (AD) patients are the extracellular senile plaques mainly composed of amyloid-β (Aβ) peptides. Aβ is generated by proteolytic processing of amyloid precursor protein (APP) via β and γ-secretases. The β-secretase APP cleaving enzyme 1 (BACE1) has become a target of intense research aimed at blocking the enzyme activity. Recent studies showed that BACE1 is involved in processing other non-APP substrates, and that other proteases are involved in APP processing. We have recently established a novel approach to inhibit Aβ production via antibodies against the β-secretase cleavage site of APP. These antibodies bind wild type and Swedish mutated APP expressed in transgenic mice brain tissues. The isolated antibodies do not bind any form of Aβ peptides. Antibody up-take experiments, using Chinese hamster ovary cells expressing wild-type APP, suggest that antibody internalization and trafficking are mediated via the endocytic pathway. Administration of antibodies to the cells growing media resulted in a considerable decrease in intracellular Aβ levels, as well as in the levels of the corresponding C-terminal fragment (C99). The relevance of intra-neuronal accumulation of mainly Aβ42 as an early event in AD pathogenesis suggests that this approach may be applicable as a novel therapeutic strategy in AD treatment.
Keywords: Alzheimer's disease, APP, Aβ, β-secretase site, BACE1, Endocytic pathway, Intracellular Aβ, Monoclonal antibodies
Current Alzheimer Research
Title: A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Volume: 4 Issue: 4
Author(s): Michal Arbel and Beka Solomon
Affiliation:
Keywords: Alzheimer's disease, APP, Aβ, β-secretase site, BACE1, Endocytic pathway, Intracellular Aβ, Monoclonal antibodies
Abstract: One of the main neuropathological lesions observed at brain autopsy of Alzheimers disease (AD) patients are the extracellular senile plaques mainly composed of amyloid-β (Aβ) peptides. Aβ is generated by proteolytic processing of amyloid precursor protein (APP) via β and γ-secretases. The β-secretase APP cleaving enzyme 1 (BACE1) has become a target of intense research aimed at blocking the enzyme activity. Recent studies showed that BACE1 is involved in processing other non-APP substrates, and that other proteases are involved in APP processing. We have recently established a novel approach to inhibit Aβ production via antibodies against the β-secretase cleavage site of APP. These antibodies bind wild type and Swedish mutated APP expressed in transgenic mice brain tissues. The isolated antibodies do not bind any form of Aβ peptides. Antibody up-take experiments, using Chinese hamster ovary cells expressing wild-type APP, suggest that antibody internalization and trafficking are mediated via the endocytic pathway. Administration of antibodies to the cells growing media resulted in a considerable decrease in intracellular Aβ levels, as well as in the levels of the corresponding C-terminal fragment (C99). The relevance of intra-neuronal accumulation of mainly Aβ42 as an early event in AD pathogenesis suggests that this approach may be applicable as a novel therapeutic strategy in AD treatment.
Export Options
About this article
Cite this article as:
Arbel Michal and Solomon Beka, A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788792
DOI https://dx.doi.org/10.2174/156720507781788792 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets The Role of Genes (and Environmental Stress) in Depression: An Update
Current Psychiatry Reviews The Role of Pericytes in Neurovascular Unit: Emphasis on Stroke
Current Drug Targets Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Diagnosis and Management of Hypertensive Emergencies Complicating Pregnancy
Current Women`s Health Reviews Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology Hydrogen Sulphide in Heart and Systemic Circulation
Inflammation & Allergy - Drug Targets (Discontinued) Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study
Current Neurovascular Research Prediction of an Interaction between Bakuchiol and Acetylcholinesterase using Adaboost
Current Bioinformatics Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Intestinal Barrier Dysfunction Participates in the Pathophysiology of Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Screening of Enzyme Inhibitors from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening Inflammatory Biomarkers in AD: Implications for Diagnosis
Current Alzheimer Research Subduing the Green-eyed Monster: Bridging the Psychopharmacological and Psychosocial Treatment Perspective in Understanding Pathological Jealousy
Current Drug Targets Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design Non-Pharmacological Treatments for ADHD in Youth
Adolescent Psychiatry Changing the Course of Alzheimers Disease: Emerging Disease Modifying Therapies
Current Psychiatry Reviews